<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/42CE62AA-63C7-447E-8692-AE40469EF4A2"><gtr:id>42CE62AA-63C7-447E-8692-AE40469EF4A2</gtr:id><gtr:firstName>Anatoli</gtr:firstName><gtr:surname>Kamali</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DCBDE587-C03E-43BF-8F6D-CE707EB1D640"><gtr:id>DCBDE587-C03E-43BF-8F6D-CE707EB1D640</gtr:id><gtr:firstName>Ubaldo</gtr:firstName><gtr:surname>Bahemuka</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DFAE67FE-E4A5-4645-8D99-152DA4ADB34A"><gtr:id>DFAE67FE-E4A5-4645-8D99-152DA4ADB34A</gtr:id><gtr:firstName>Jennifer</gtr:firstName><gtr:surname>Serwanga</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FF4F6CC0-FE8D-4697-82B9-391A29BBB2B8"><gtr:id>FF4F6CC0-FE8D-4697-82B9-391A29BBB2B8</gtr:id><gtr:firstName>Freddie</gtr:firstName><gtr:surname>Kibengo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7E940F57-EFFB-4097-98AC-7474D6E46282"><gtr:id>7E940F57-EFFB-4097-98AC-7474D6E46282</gtr:id><gtr:firstName>Juliet</gtr:firstName><gtr:surname>Ndibazza</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_1204%2F7"><gtr:id>91A64619-843F-4025-A470-20F090405185</gtr:id><gtr:title>HIV EPIDEMIOLOGY AND PREVENTION / International AIDS Vaccine Initiative</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_1204/7</gtr:grantReference><gtr:abstractText>The HIV vaccines research aims to contribute to HIV vaccine development, trial design and evaluating potential HIV vaccines in human clinical trials. There is a need to establish clinical cohorts at high risk of HIV infection, to assess infection rates, retention, acceptability and reasons for refusal to participate, if any in such trials. The findings inform recruitment and retention strategies, volunteer tracking and follow up systems; local strategies to identify reasons for volunteer loss to follow-up. The work also helps to develop and strengthen operational tools that will be useful in the successful conduct of large efficacy trials.</gtr:abstractText><gtr:technicalSummary>The overall aim is to conduct studies that inform the design for a protective HIV vaccine. Our work aims at conducting studies of significance to HIV vaccine development and builds on our experience in conducting clinical trials. This work is in collaboration with and support from International AIDS Vaccine Initiative (IAVI).
Objectives: 
1. To recruit, follow up, counsel, and test at-risk volunteers for HIV infection
2. Estimate incidence of HIV infection in at-risk volunteers
3. Establish reliable and efficient volunteer contact and tracking systems to maximize volunteer retention, and determine reason(s) for loss of volunteers to follow-up.
4. Evaluate risk factors for incident HIV infection
5. Recruit and follow up a cohort of recently HIV infected volunteers to inform HIV vaccine design
6. To design and conduct new studies that have significance to HIV vaccine development and trial design
7. To evaluate potential HIV vaccines in phase I/II clinical trials 
Objectives 1-4 are through a prospective, open cohort, observational study that recruits and follows up adult male and female adult volunteers, from 18-49 years of age at risk for HIV infection that meet the study inclusion criteria, and are willing to comply with protocol requirements.
Objective 5 is a prospective, observational, multi-centre study that evaluates laboratory, clinical, immunologic and viral markers of disease progression in recently HIV-infected volunteers.
To answer objective 6, studies that inform vaccine development and design are conducted such willingness to participate and be retained in HIV vaccine trials by enrolling volunteers in simulated vaccine efficacy trial.
Objective 7: we aim to evaluate potential HIV vaccines as and when good candidates become available. Currently we are planning a phase I double blind placebo-controlled clinical trial to evaluate the safety and immunogenicity of the combination of DNA-HIV-PT123 and AIDSVAX&amp;reg; B/E in HIV-1-uninfected adult participants with or without underlying Schistosoma mansoni infection.</gtr:technicalSummary><gtr:fund><gtr:end>2018-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2819060</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_1204/7</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>